systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-212Research ArticleСТАТЬИARTICLESВозможности применения блокатора рецепторов к ангиотензину лозартана при комбинированной терапии артериальной гипертензииThe use of angiotensin receptor blocker losartan in the combinational therapy of arterial hypertensionЗагидуллинН. Ш.noemail@neicon.ruЗагидуллинШ. З.noemail@neicon.ruГОУ ВПО Башкирский государственный медицинский университет РосздраваRussian Federation200923122022641215Copyright © Загидуллин Н.Ш., Загидуллин Ш.З., 20222022Загидуллин Н.Ш., Загидуллин Ш.З.Загидуллин Н.Ш., Загидуллин Ш.З.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/212лозартанЛориставысокие дозыартериальная гипертензиягидрохлоротиазидlosartanLoristahigh dosesarterial hypertensionhydrochlorothiazideReferencesБеленков Ю.Н. и рабочая группа исследователей ЭПИГРАФ-2. Эналаприл плюс Индапамид в лечение АГ: оценка эффективности и безопасности Рациональной Фармакотерапии. Применение нефиксированной комбинации Эналаприла и Индапамида (Энзикс). Дизайн и основные результаты исследования ЭПИГРАФ-2. Сердце. 2005; 4 (5): 277-86.Беленков Ю.Н. и рабочая группа исследователей ЭПИГРАФ-2. Эналаприл плюс Индапамид в лечение АГ: оценка эффективности и безопасности Рациональной Фармакотерапии. Применение нефиксированной комбинации Эналаприла и Индапамида (Энзикс). Дизайн и основные результаты исследования ЭПИГРАФ-2. Сердце. 2005; 4 (5): 277-86.Лопатин Ю.М. Фиксированные низкодозовые комбинации антигипертензивных средств с позиции препаратов первого выбора для лечения артериальной гипертонии. Сердце. 2006; 4 (3): 113-55.Лопатин Ю.М. Фиксированные низкодозовые комбинации антигипертензивных средств с позиции препаратов первого выбора для лечения артериальной гипертонии. Сердце. 2006; 4 (3): 113-55.Фомин И.В. Артериальная гипертония в Российской Федерации - последние десять лет. Что дальше? Сердце. 2007; 6 (3): 120-3.Фомин И.В. Артериальная гипертония в Российской Федерации - последние десять лет. Что дальше? Сердце. 2007; 6 (3): 120-3.Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.Christensen DB, Williams B, Goldberg HI et al. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care 1999; 35 (11): 1164-70.Christensen DB, Williams B, Goldberg HI et al. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care 1999; 35 (11): 1164-70.Coca A, Sobrino J, Soler J et al. Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension. J Cardiovasc Pharmacol 2002; 39: 824-33.Coca A, Sobrino J, Soler J et al. Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension. J Cardiovasc Pharmacol 2002; 39: 824-33.Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part2: short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-8.Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part2: short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-8.Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.Flack JM, Saunders E, Gradman A et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 2001; 23: 1193-208.Flack JM, Saunders E, Gradman A et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 2001; 23: 1193-208.F?rster A, Smolka W, Jung C et al. Fixed-dose combination of losartan/hydrochlorothiazide 100mg/25mg: safety and efficacyon office and 24-h blood pressure. MMW Fortschr Med 2007; 149: 111-8.F?rster A, Smolka W, Jung C et al. Fixed-dose combination of losartan/hydrochlorothiazide 100mg/25mg: safety and efficacyon office and 24-h blood pressure. MMW Fortschr Med 2007; 149: 111-8.Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.Gradman AH, Brady WE, Gazdick LP et al. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12,5 mg in the treatment of moderate-to-severe essential hypertension. Clin Ther 2002; 24: 1049-61.Gradman AH, Brady WE, Gazdick LP et al. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12,5 mg in the treatment of moderate-to-severe essential hypertension. Clin Ther 2002; 24: 1049-61.Lakshman MR, Reda DJ, Materson BJ et al. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999; 159: 551-8.Lakshman MR, Reda DJ, Materson BJ et al. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999; 159: 551-8.Longobardi G, Corbi G, Cacciatore F et al. Effect of Losartan in Treatment of Exercise-Induced Myocardial Ischemia Am J Cardiol 2007; 100: 1517-21.Longobardi G, Corbi G, Cacciatore F et al. Effect of Losartan in Treatment of Exercise-Induced Myocardial Ischemia Am J Cardiol 2007; 100: 1517-21.Lubsen J, Wagener G, Kirwan B et al. ACTION (A Coronary disease Trial Investigating Outcome with Niefedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23: 642-8.Lubsen J, Wagener G, Kirwan B et al. ACTION (A Coronary disease Trial Investigating Outcome with Niefedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23: 642-8.Moen MD, Wagstaff AJ. Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs 2005; 65: 2657-74.Moen MD, Wagstaff AJ. Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs 2005; 65: 2657-74.Naidoo DP, Sareli P, Marin F et al. Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies. Adv Ther 1999; 16: 187-99.Naidoo DP, Sareli P, Marin F et al. Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies. Adv Ther 1999; 16: 187-99.Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensiveagents on cardiovascular events in patients with coronary diseaseand normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-25.Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensiveagents on cardiovascular events in patients with coronary diseaseand normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-25.Okano Y, Tamura K, Kuji T et al. Effects of Angiotensin II Receptor Blockers on Relationships Between 24-Hour Blood Pressure, Autonomic Function, and Health-Related QOL. Clinical and Experimental Hypertension 2009; 31: 250-8.Okano Y, Tamura K, Kuji T et al. Effects of Angiotensin II Receptor Blockers on Relationships Between 24-Hour Blood Pressure, Autonomic Function, and Health-Related QOL. Clinical and Experimental Hypertension 2009; 31: 250-8.Oparil S, Aurup P, Snavely D et al. Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. Am J Cardiol 2001; 87: 721-6.Oparil S, Aurup P, Snavely D et al. Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. Am J Cardiol 2001; 87: 721-6.Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patinets with symptomatic heart failure randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patinets with symptomatic heart failure randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.Soffer BA, Wright JrJT, Pratt JH et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-7.Soffer BA, Wright JrJT, Pratt JH et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-7.Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J 2000; 139: 174-83.Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J 2000; 139: 174-83.
The authors declare that there are no conflicts of interest present.